戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 n due to deficient vATPase and its rescue by beta2-adrenergic agonists.
2 inically relevant airspace concentrations of beta2-adrenergic agonists a) stimulate maximal cAMP-depe
3 e findings of increased risk associated with beta2-adrenergic agonist agents together with stress rel
4  of beta-blockers was less common but use of beta2-adrenergic agonist agents was more common in patie
5 ung function measurements, responsiveness to beta2-adrenergic agonists, and health care use.
6                                              beta2-adrenergic agonists are an effective treatment for
7           The precise mechanism of action of beta2-adrenergic agonists at the NMJ is not fully unders
8 f Parkinson disease (PD) associated with the beta2 adrenergic agonist (beta2-agonist) salbutamol.
9 maximize reverse remodeling, followed by the beta2 adrenergic agonist clenbuterol.
10 sms by which corticosteroids and long-acting beta2 -adrenergic agonists confer protection against pat
11                  Conversely, administering a beta2-adrenergic agonist decreases GVHD in mice housed a
12  the long-term follow-up for the addition of beta2-adrenergic agonists for a cohort of patients with
13       In this study, we investigated whether beta2-adrenergic agonists improve both neurotransmission
14 al studies are required to determine whether beta2-adrenergic agonists improve outcome in patients wi
15                     The working mechanism of beta2-adrenergic agonists in myasthenic patients is not
16 , a potent, highly specific, and long-acting beta2-adrenergic agonist, induces renal mitochondrial bi
17 cytes with glucagon but not by that with the beta2-adrenergic agonist isoproterenol (ISO).
18  have shown that combinations of long-acting beta2-adrenergic agonists (LABAs) and long-acting muscar
19 re used to study the effect of salbutamol, a beta2-adrenergic agonist, on synaptic structure and func
20  report that isoproterenol (ISO) and related beta2-adrenergic agonists reacidify lysosomes in PSEN1 K
21 structure resulting from the addition of the beta2-adrenergic agonist salbutamol to the anticholinest
22 ate a specific impairment in the capacity of beta2-adrenergic agonists to promote lipolysis in subcut
23                  With continuous exposure to beta2-adrenergic agonists, vascular tissue becomes desen
24 e issue of whether regular use of an inhaled beta2-adrenergic agonist worsens airflow and clinical ou